中文摘要：

目的：探讨肝癌患者血清 miR-200a 表达及其临床病理特征之间的关系。方法运用实时定量PCR技术检测36例肝癌患者和21例健康人血清标本中miR-200a的表达情况，分析血清miR-200a的表达水平与肝癌患者临床病理参数之间的关系。血清中 AFP 值从临床资料中获取。结果36例肝癌患者miR-200a的表达水平为4.63±1.31，21例健康人对照为6.05±0.51，两者差异有统计学意义（P＜0.05）。在36例肝癌患者中，血清miR-200a表达水平与肝癌分化程度、TNM分期及AFP有关（P＜0.05），而与性别、年龄、抽烟、饮酒、HBV、肝硬化无关（P＞0.05）。结论血清 miR-200a 表达水平可作为新的生物学指标对肝癌的诊断具有一定的价值。

英文摘要：

Objective To investigate the expression level of miR-200a in serum of patients with hepatocellular carcinoma and its clinical significance. Methods Real time PCR was used to detect the expression of miR-200a in the serum of 36 patients with hepatocellular carcinoma and 21 normal controls, to analysis the relationship between the expression of serum miR-200a and clinical pathological parameters in patients with hepatocellular carcinoma. The AFP expression was got from clinical data. Results The expression level of miR-200a was 4.63 ＆#177;1.31 in 36 hepatocellular carcinoma patients and 6.05＆#177;0.51 in 21 normal control .Serum miR-200a expression level in 36 patients was significantly lower than that in normal control （P＆lt;0.05）. Serum miR-200a expression was significantly associated with tumor differentiation, TNM and AFP （P＆lt;0.05）. There were no correlation between serum miR-200a expression level and sex, age, smoked cigarettes, consumed alcohol, HBV, cirrhosis（P＆gt;0.05）. Conclusion Our data confirms a role for serum miR-200a as a novel cancer biomarker in hepatocellular carcinoma.